PubMed ID: 35461831 Author(s): Scott IU, VanVeldhuisen PC, Oden NL, Ip MS, Blodi BA; SCORE2 Investigator Group. Month 60 Outcomes After Treatment Initiation With Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central …
WRC
Artificial intelligence-based strategies to identify patient populations and advance analysis in age-related macular degeneration clinical trials.
PubMed ID: 35525297 Author(s): Yaghy A, Lee AY, Keane PA, Keenan TDL, Mendonca LSM, Lee CS, Cairns AM, Carroll J, Chen H, Clark J, Cukras CA, de Sisternes L, Domalpally A, Durbin MK, Goetz KE, …
Long-term Outcomes of Adding Lutein/Zeaxanthin and ω-3 Fatty Acids to the AREDS Supplements on Age-Related Macular Degeneration Progression: AREDS2 Report 28.
PubMed ID: 35653117 Author(s): Chew EY, Clemons TE, Agrón E, Domalpally A, Keenan TDL, Vitale S, Weber C, Smith DC, Christen W; AREDS2 Research Group. Long-term Outcomes of Adding Lutein/Zeaxanthin and ω-3 Fatty Acids to …
Reservoir Technique: A Novel Method for Pressure-Controlled Silicone Oil Infusion Using the Constellation Vitrectomy System.
PubMed ID: 30681642 Author(s): Boeke PS, Altaweel MM. Reservoir Technique: A novel method for Pressure-Controlled Silicone Oil Infusion using the Constellation Vitrectomy System. Retina. 2022 Jun 1;42(6):1211-1213. doi: 10.1097/IAE.0000000000002458. PMID 30681642 Journal: Retina (Philadelphia, Pa.), …
Artificial Intelligence Algorithms in Diabetic Retinopathy Screening.
PubMed ID: 35438458 Author(s): Zafar S, Mahjoub H, Mehta N, Domalpally A, Channa R. Artificial Intelligence Algorithms in Diabetic Retinopathy Screening. Curr Diab Rep. 2022 Jun;22(6):267-274. doi: 10.1007/s11892-022-01467-y. Epub 2022 Apr 19. Review. PMID 35438458 …
SCORE2 Report 17: Macular thickness fluctuations in anti-VEGF-treated patients with central or hemiretinal vein occlusion.
PubMed ID: 34842984 Author(s): Scott IU, Oden NL, VanVeldhuisen PC, Ip MS, Blodi BA; SCORE2 Investigator Group. SCORE2 Report 17: Macular thickness fluctuations in anti-VEGF-treated patients with central or hemiretinal vein occlusion. Graefes Arch Clin …
Baseline Characteristics and Outcomes After Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema in Participants With Hemiretinal Vein Occlusion Compared With Participants With Central Retinal Vein Occlusion: Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2) Report 18.
PubMed ID: 35323843 Author(s): Scott IU, Oden NL, VanVeldhuisen PC, Ip MS, Blodi BA; SCORE2 Study Investigator Group. Baseline characteristics and outcomes after Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema in participants with Hemiretinal …
Disease-modifying effects of ranibizumab for central retinal vein occlusion.
PubMed ID: 34613454 Author(s): Huang JM, Khurana RN, Ghanekar A, Wang PW, Day BM, Blodi BA, Domalpally A, Quezada-Ruiz C, Ip MS. Disease-modifying effects of ranibizumab for central retinal vein occlusion. Graefes Arch Clin Exp …
Comparison of ETDRS 7-Field to 4-Widefield Digital Imaging in the Evaluation of Diabetic Retinopathy Severity.
PubMed ID: 35015059 Author(s): Blodi BA, Domalpally A, Tjaden AH, Barrett N, Chew EY, Knowler WC, Lee CG, Pi-Sunyer X, Wallia A, White NH, Temprosa M. Comparison of ETDRS 7-field to 4-widefield digital imaging in …